

Bruce D. Cheson, MD

Professor of Medicine

Director of Hematology Research

Georgetown University Hospital

Lombardi Comprehensive Cancer Center

Washington, DC

Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?

Welcome to *Managing Hodgkin Lymphoma*. My name is Bruce Cheson and I am deputy chief of hematology/oncology and head of hematology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center. I am frequently asked, “Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?” CD30 is important in making the diagnosis of classical Hodgkin lymphoma, but it is also present on a number of other lymphoid malignancies, notably anaplastic large cell lymphoma, which is why it has such a high response rate to brentuximab vedotin, the anti-CD30 antibody drug conjugate. But that is not the only lymphoid malignancy that expresses this antigen. For example, there are other T-cell lymphomas, including cutaneous T-cell lymphoma, and in fact there are B-cell lymphomas. About a quarter or so of diffuse large B-cell lymphomas also express CD30 and some of these patients do respond to brentuximab vedotin as well. So thank you for viewing this activity. For additional resources, please view the other educational activities on *ManagingHodgkinLymphoma.com*.